Pembrolizumab plus chemotherapy for advanced gastric cancer.

Competing Interests: SD reports being a consultant or having an advisory role for BMS (related to checkpoint inhibitors); receiving research funding, medication supply, or both from Incyte (related to checkpoint inhibitors); and having speaker roles for Servier, BMS, and Benecke. HWMvL declares being a consultant or having an advisory role for Amphera, Anocca, Astellas Pharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Daiichi Sankyo, Dragonfly, MSD, Myeloid Therapeutics, and Servier; receiving research funding, medication supply, or both from Auristone, Incyte, Merck, ORCA Therapeutics, and Servier; and having speaker roles for Astellas Pharma, BeiGene, Benecke, BMS, Daiichi Sankyo, JAAP, Medtalks, Novartis, Springer, and Travel Congress Management B V. TS declares no competing interests.